A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
European Journal of Cancer2013Vol. 49(9), pp. 2077–2085
Citations Over TimeTop 10% of 2013 papers
Jeffrey R. Infante, Kyriakos P. Papadopoulos, Johanna C. Bendell, Amita Patnaik, Howard A. Burris, Drew Rasco, Suzanne F. Jones, Lon Smith, Donna S. Cox, M. Durante, Kevin M. Bellew, Joo‐Hyun Park, Ngocdiep T. Le, Anthony W. Tolcher
Related Papers
- → Pharmacokinetics, Safety, and Tolerability of Single‐ and Multiple‐Dose Once‐Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo‐Controlled Study(2020)21 cited
- → Single- and Multiple-Dose Pharmacokinetics and Tolerability of Limaprost in Healthy Chinese Subjects(2015)1 cited
- Study on Pharmacokinetics of PLGA-Gemcitabine Sustained-Release Microspheres in Nude Mice with Pancreatic Cancer(2010)
- → Safety, tolerability, and pharmacokinetics of a novel, selective antiprogestagen (Org 31710) in healthy male volunteers(1998)2 cited
- → A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers.(2020)